1. Home
  2. JGH vs ALT Comparison

JGH vs ALT Comparison

Compare JGH & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JGH
  • ALT
  • Stock Information
  • Founded
  • JGH 2014
  • ALT 1997
  • Country
  • JGH United States
  • ALT United States
  • Employees
  • JGH N/A
  • ALT N/A
  • Industry
  • JGH Investment Managers
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • JGH Finance
  • ALT Health Care
  • Exchange
  • JGH Nasdaq
  • ALT Nasdaq
  • Market Cap
  • JGH 306.4M
  • ALT 292.0M
  • IPO Year
  • JGH N/A
  • ALT N/A
  • Fundamental
  • Price
  • JGH $13.40
  • ALT $3.54
  • Analyst Decision
  • JGH
  • ALT Strong Buy
  • Analyst Count
  • JGH 0
  • ALT 6
  • Target Price
  • JGH N/A
  • ALT $17.40
  • AVG Volume (30 Days)
  • JGH 73.9K
  • ALT 2.8M
  • Earning Date
  • JGH 01-01-0001
  • ALT 08-12-2025
  • Dividend Yield
  • JGH 9.85%
  • ALT N/A
  • EPS Growth
  • JGH N/A
  • ALT N/A
  • EPS
  • JGH N/A
  • ALT N/A
  • Revenue
  • JGH N/A
  • ALT $20,000.00
  • Revenue This Year
  • JGH N/A
  • ALT N/A
  • Revenue Next Year
  • JGH N/A
  • ALT $346,228.97
  • P/E Ratio
  • JGH N/A
  • ALT N/A
  • Revenue Growth
  • JGH N/A
  • ALT N/A
  • 52 Week Low
  • JGH $10.36
  • ALT $2.90
  • 52 Week High
  • JGH $12.85
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • JGH 60.46
  • ALT 39.37
  • Support Level
  • JGH $13.34
  • ALT $3.51
  • Resistance Level
  • JGH $13.60
  • ALT $3.78
  • Average True Range (ATR)
  • JGH 0.07
  • ALT 0.18
  • MACD
  • JGH -0.01
  • ALT 0.05
  • Stochastic Oscillator
  • JGH 50.62
  • ALT 35.84

About JGH Nuveen Global High Income Fund of Beneficial Interest

Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: